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Abstract
Objective: To establish the relationship between production of glutathione and the therapeutic
response to amodiaquine (AQ) monotherapy in Plasmodium falciparum non-complicated malaria
patients.
Methodology: Therapeutic response to AQ was evaluated in 32 patients with falciparum malaria
in two townships of Antioquia, Colombia, and followed-up for 28 days. For every patient, total
glutathione and enzymatic activity (glutathione reductase, GR, and γ-glutamylcysteine synthetase, γ-
GCS) were determined in parasitized erythrocytes, non-infected erythrocytes and free parasites,
on the starting day (day zero, before ingestion of AQ) and on the day of failure (in case of
occurrence).
Results: There was found an AQ failure of 31.25%. Independent of the therapeutic response, on
the starting day and on the day of failure, lower total glutathione concentration and higher GR
activities in parasitized erythrocytes were found, compared with non-infected erythrocytes (p <
0.003). In addition, only on the day of failure, γ-GCS activity of parasitized erythrocytes was higher,
compared with that of healthy erythrocytes (p = 0.01). Parasitized and non-parasitized erythrocytes
in therapeutic failure patients (TF) had higher total glutathione on the starting day compared with
those of adequate clinical response (ACR) (p < 0.02). Parasitized erythrocytes of TF patients
showed lower total glutathione on the failure day, compared with starting day (p = 0.017). No
differences was seen in the GR and γ-GCS activities by compartment, neither between the two
therapeutic response groups nor between the two treatment days.
Conclusion: This study is a first approach to explaining P. falciparum therapeutic failure in humans
through differences in glutathione metabolism in TF and ACR patients. These results suggest a role
for glutathione in the therapeutic failure to antimalarials.
Background
Malaria is a parasitic disease, which has the highest mor-
bidity/mortality rate in tropical countries [1]. The causal
agent with the highest lethality rate for this disease and
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resistance to antimalarials in the world is Plasmodium fal-
ciparum [2]. In Colombia, there have been reports about
resistance of P. falciparum to antimalarial drugs since
1960. In Antioquia, Colombia, 97% and 30% of thera-
peutic failure to the 4-aminoquinolines, chloroquine
(CQ) and amodiaquine (AQ) respectively, have been
reported [3,4]. Therefore, CQ is no longer used in Antio-
quia and the use of AQ in combination with sulphadox-
ine-pyrimethamine (SP) was suggested since 1985 and
until 2006 [4].
Haemoglobin is degraded by Plasmodium during intraer-
ythrocytic stages in a process where haem is released and
converts itself into a toxic molecule, because this parasite
lacks haem oxygenase and produces reactive oxygen spe-
cies (ROS) [5]. The parasite detoxifies haem simultane-
ously by polymerization and degradation. In the first case,
the parasite converts almost 30% of haem in haemozoin
or malarial pigment. Haem toxicity is avoided too,
through cytosolic degradation by reduced glutathione
(GSH). This can degrade haem, whether it is free in solu-
tion or it is bound nonspecifically to protein, when dis-
solved in erythrocyte membranes or loaded into intact
erythrocytes [6,7]Plasmodium is endowed with a machin-
ery to detoxify ROS. This antioxidant system comprises
GSH and thioredoxin redox system, superoxide dis-
mutase, NADPH and a vigorous pentose phosphate path-
way, but it lacks catalase and glutathione peroxidase [8-
10].
Glutahione is synthesized by the step-limiting enzyme γ-
glutamyl cysteine synthetase (γ-GCS) and by glutathione
synthetase (GS). This thiol found in its reduced state
inside all cells, contributes to maintaining intracellular
redox state; besides, it has been suggested that GSH is
involved in drug resistance both as a cofactor for enzy-
matic reactions and by helping to mediate resistance as a
source of reductive detoxification of haem. After its reac-
tion with a free radical, GSH changes its oxidation state
(GSSG). Glutathione reductase (GR) NADPH is the
enzyme responsible for keeping glutathione in its reduced
state [9,10].
The resistance of P. falciparum to the 4-aminoquinolines,
such as CQ, has been shown to be associated with modi-
fication of drug transport by the membrane proteins P-
glycoprotein homologue 1(Pgh1) and the P. falciparum
chloroquine resistance transporter (pfcrt) [10]. An addi-
tional mode of resistance has been suggested that is con-
nected to an increase of GSH levels, which compete with
the drug for degrading the haem toxin [7].
Meierjohann et al. [11] showed that growth inhibition of
P. falciparum CQ-sensitive strain (3D7) by L-buthionine-
(S, R)-sulfoximine (BSO), a specific inhibitor of γ-GCS
and by methylene blue (MB), an inhibitor of the GR, was
significantly more pronounced than inhibition of P. falci-
parum CQ-resistant strain (Dd2) growth by these drugs.
These results correlate with the higher levels of total glu-
tathione in P. falciparum Dd2. In addition, they suggest
that maintenance of intracellular GSH in P. falciparum
Dd2 is mainly dependent on GSH synthesis, whereas in P.
falciparum 3D7 is regulated via GR [11].
Studies in vivo on Plasmodium berghei-infected mice con-
firm that drugs which alter GSH intracellular concentra-
tions, change Plasmodium susceptibility to the CQ [12].
The correlation between GSH level and resistance CQ is
supported by the higher expression of γ-GCS [13]. It has
been shown that acquisition of CQ resistance in P. berghei
is associated with a significant increase in parasite glucose
6-phosphate deshydrogenase (G6PD) activity and GSH.
Combination of CQ with an inhibitor of G6PD or BSO
significantly increased sensitivity of resistant parasites to
CQ and increased the survival period of the infected mice
[14]. Other studies in vivo on P. berghei and Plasmodium
vinckei-infected mice showed that drugs, such as acetami-
nophen, indomethacin and disulphiram, which produce
an indirect decrease in GSH, potentiate the antimalarial
action of CQ and AQ sub-curative doses [15].
This study examined whether there exists a relationship
between the total glutathione level in patients with
malaria by P. falciparum and therapeutic failure to AQ,
since CQ has not actually been used as a monotherapy.
Possible variations of total glutathione levels and GR and
γ-GCS activities were determined in function of the thera-
peutic response in parasitized erythrocytes, non-infected
erythrocytes and free parasites. It should help to under-
stand the phenomena of therapeutic failure to the 4-ami-
noquinolines.
Materials and methods
Within the framework of the evaluation of the resistance
to antimalarics by RAVREDA (Red Amazóniza de Vigilan-
cia a la Resistencia de Drogas Antimaláricas), during 2003
and 2004, clinical and parasitological therapeutic
response to monotherapy with AQ was assessed in
patients with non-complicated P. falciparum malaria,
according to the WHO Protocol 2000 that classifies the
response in adequate clinical response (ACR) and thera-
peutic failure (TF). Patients were from Turbo and El Bagre,
two townships in Antioquia, Colombia. In this study, the
therapeutic failure was higher than permitted (>26%) by
National Health Ministry treatment guidelines in Colom-
bia and, therefore, the study was carried out only with 32
patients. Initial malaria diagnosis was carried out with
thick and thin smear; these were Field and Giemsa stained
respectively. Parasitaemia was calculated by counting the
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of venous blood with anticoagulant CPD were taken on
the starting day (zero day, before ingestion of AQ) and
failure day for those patients who failed (before the rescue
treatment). Samples were kept in liquid nitrogen until
their processing. Total glutathione concentration and the
enzymatic activity of GR and γ-GCS were determined in
infected erythrocytes, non-parasitized erythrocytes and
free parasites.
Ethical considerations
A written informed consent from each patient was
obtained and signed before being included in the research
project. This study was approved by the Ethics Committee
of the Facultad de Medicina of the Universidad de Antio-
quia.
Sample thawing
Blood samples were thawed according to the workshop
protocol suggested in the course "Molecular Approaches
to Malaria" – International Centre for Engineering and
Biotechonology [17].
Separation of parasitized and non-parasitized 
erythrocytes by Percoll gradients
In thawed samples, parasitized and non-parasitized red
blood cells were separated by Percoll gradients according
to the methodology described by Omodeo-Sale et al 2003
with some modifications [18]. The thawed red blood cells
pellet was taken to a haematocrit of 20 – 25% with serum-
free RPMI and fractionated onto a Percoll/4% sorbitol
(wt/vol) gradient: (from bottom to top) 90, 80, 70, 60
and 40% percoll. Resuspended erythrocytes were over-lay-
ered on the gradient and centrifuged 2000 RPM at room
temperature (RT) for 20 min. Three layers were obtained:
an upper layer which corresponds to parasitized red blood
cells; an intermediate layer which contained a mix of par-
asitized and non-infected erythrocytes, and a bottom layer
corresponding to non-parasitized erythrocytes. The upper
layer was removed. To enrich the non-parasitized erythro-
cyte fraction, the other two lower layers were mixed and
fractionated again in the same Percoll-sorbitol gradient.
All layers were washed twice with fresh serum-free RPMI.
5 μl from the upper layer and 2.5 μl of the bottom layer
were suspended in 200 μl of distilled water.
Separation of free parasites from parasitized red blood 
cells infected with P. falciparum
The free parasites were obtained according to Hsiao pro-
tocol with some modifications [19]: the pellet of parasit-
ized red blood cells obtained by separation with Percoll
gradients was taken and the same volume of 0.1%
saponin was added; it was mixed with vortex and then
incubated during 10 minutes at 37°C, by mixing gently. It
was centrifuged at 2,000 rpm for 15 minutes at RT. The
pellet obtained had the free parasites which were washed
with buffer phosphate by centrifugation at 10,000 rpm
during 5 minutes at RT until the red color disappeared.
The pellet of free parasites was diluted in 200 μl of dis-
tilled water.
Enzymatic activity and quantification of total glutathione
The enzymatic activity of glutathione reductase (GR) and
γ-glutamylcysteine synthetase (γ-GCS), protein concentra-
tion and total glutathione content were determined in
parasitized and non-parasitized erythrocytes and in free
parasites, and were carried out in duplicate.
Determination of glutathione reductase activity
This was carried out according to the method described by
Calberg I and Mannervik B 1985 [20]. Glutathione reduct-
ase enzymatic activity is based on the decay of the absorb-
ance of NADPH at 340 nm measured during a 5-minute
period at 30°C.
Determination of γ-glutamyl cysteine synthetase activity
This was determined according to the method described
by Estrada del Cueto et al. 1999 [21]. This technique
assumes that enzymatic activity is equal to the change in
NADH absorbance at 340 nm during 60 minutes at 37°C.
The absorbance obtained while adding pyruvate/kinase
enzymatic mixture (PK/LDH Sigma-Aldrich) was taken as
zero time; it was incubated and absorbance was read
again.
Determination of total glutathione concentration by HPLC
The concentration of total glutathione (oxidized and
reduced) was analysed as mBBr derivatives (thiolyte® Cal-
biochem) by reversed-phase HPLC. The method sug-
gested by Luersen et al. 2000 was followed with some
modifications [22]: to 20 μl of sample (parasitized eryth-
rocytes, non-infected erythrocytes or free parasites) in 1.5-
ml Eppendorf tubes placed on ice and protected from
light were added 10 μl of NABH4, in 0.066 M NaOH and
33% (v/v) dimethyl sulphoxide (DMSO), 6 μl of 2 mM
EDTA and 1.65 mM dithiothreitol, 6 μl of octanol and 14
μl of 1.8 M HCl. After three min 70 μl of 1 M ethylmor-
pholine buffer (pH 8.5), 134 μl of deionized water and 14
μl of 5 mM thiolyte® were added. The derivatization was
carried out at 70°C for 10 min in the dark and was termi-
nated by adding 26 μl of 100% acetic acid. After 20 min
on ice in the dark, the sample was extracted with 200 μl of
dichloromethane and centrifuged at 10,000 rpm at RT for
two minutes. The supernatant, which is the water-soluble
phase, was taken and filtered through a 0.45-μm nylon
membrane. The filtered samples were stored at -20°C,
protected from light until their injection in the HPLC. 20
μl obtained from the water-soluble phase were injected on
to a LiChroCART® 100 RP-18 (5.0 μm) reverse phase
HPLC. The column was eluted at a flow rate of 0.55 ml/
min by the following gradient of solvent A (0.25% aceticMalaria Journal 2007, 6:47 http://www.malariajournal.com/content/6/1/47
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acid) and solvent B (100% acetonitrile): 0 min, 100% sol-
vent A; 5 min, 90% solvent A; 20 min, 85% solvent A, 25
min, 0% solvent A. The effluent was monitored by a fluo-
rescence spectrophotometer (excitation 400 nm; emission
475 nm). Under these conditions, the glutathione-thi-
olyte®  adduct had a retention time of 13.9 min and
cysteine-thiolyte® of 10.07 min. Cysteine (Cys) and GSH
were used as external standards with recovery rate of 123.8
± 6.6% and 74.8 ± 8.2% respectively. Two calibration
curves were elaborated due to concentration variation of
glutathione in the samples and in doing the regression
analysis (lineal model). The obtained sensibility was 3.2
pmol, which is found in the quantity range detected when
working derivatized compounds with monobromobi-
mane [23].
Determination of protein concentration
Protein determination to relate enzymatic activity and the
glutathione content was carried out by the method of
Lowry et al 1951 [24].
Statistical analysis
The data were analysed by the one-way variance analysis
(Mann-Whitney test) in order to compare mean of total
glutathione concentration and GR and γ-GCS activities in
parasitized red blood cells, non-parasitized and free para-
sites in function of the therapeutic response (ACR and
TF). A matching test was applied (Wilcoxon test) to com-
pare the means in both days (starting and failure day) in
the group of patients that had therapeutic failure. A corre-
lation analysis and a simple linear regression were made
to assess the association between GR and γ-GCS activity in
ACR and FT patients with parasitaemia, and glutathione
concentration in all cellular compartments. A confidence
level of 95% (α = 0.05 o p ≤ 0.05) was applied to all esti-
mates and statistical tests. The program SpSS 14 was used
for the statistical analysis.
Results
The therapeutic response to monotherapy with AQ was
assessed during 28 days in 32 patients with non-compli-
cated malaria by P. falciparum; 21 patients came from the
township of Turbo, and 11 from El Bagre. Mean age was
27 years (8 – 60) old and 17 of them were male. The 32
patients evaluated were divided into two groups according
to therapeutic response to AQ; 22 of them had ACR and
10 TF (31.25%). On the starting day (zero day), mean par-
asitaemia was 8,699 (880 – 31,960) rings/μl for ACR
patients and 9,944 (580 – 38,400) rings/μl for TF patients;
on the failure day, mean parasitaemia was 1,681 (26 –
8,640) parasites/μl.
Glutathione concentration and enzymatic activity in 
malaria patients before treatment (starting day)
On the starting day for all patients, total glutathione and
GR and γ-GCS activities between parasitized and non-par-
asitized erythrocytes were compared. Non-parasitized
erythrocytes had higher total glutathione than the infected
ones, both in ACR as well as FT patients (ACR = 16.324 ±
4.992 nmol/mg protein vs 5.612 ± 2.119 nmol/mg pro-
teins, p < 0.001 and TF = 21.636 ± 4.149 nmol/mg protein
vs 11.725 ± 4.833 nmol/mg proteins, p = 0.003). Also for
both therapeutic response groups was found that GR
activity was statistically lower in the healthy erythrocytes
compared to parasitized erythrocytes (ACR = 23.691 ±
8.145 UI/mg protein vs 34.927 ± 14.777 UI/mg proteins,
p  = 0.015 and TF = 18.594 ± 5.442 UI/mg protein vs
30.103 ± 10.171 UI/mg proteins, p = 0.021). Differences
were not found in the γ-GCS activity between both com-
partments for any of two groups of therapeutic response
(p > 0.05) (Table 1).
When the analysis was done based on the therapeutic
response, we found that TF patients have higher total glu-
tathione in parasitized erythrocytes and in non-parasit-
ized erythrocytes compared with those that had ACR (p <
0.016). There were no differences for GR and γ-GCS activ-
ities for either therapeutic response group (Table 1).
The glutathione content in free parasites was the same in
all patients, sometimes it was below the method detection
limit (3.2 pmol). Differences in GR and γ-GCS activities
were not found for either therapeutic response group.
In correlation analysis and a simple linear regression, TF
patients presented a 58% correlation between parasitae-
mia and GR activity of free parasites, and statistically sig-
nificant correlations were not found in any of the cellular
compartments for ACR patients (always r2 < 0.5, data non-
shown).
Glutathione and enzymatic activity in FT patients
Total glutathione and the activity of both enzymes were
studied in the 10 TF patients. On the failure day, it was
found that infected erythrocytes had lower total glutath-
ione and higher GR y γ-GCS activities compared with non-
parasitized erythrocytes (p < 0.014) (Table 1). In the anal-
ysis of TF patients based on the day (starting and failure
day), was seen a significant decrease in glutathione con-
centration of parasitized erythrocytes on failure day
(11.725 ± 4.833 vs 5.847 ± 2.582, p = 0.017) and there
was no important changes in total glutathione of non-par-
asitized erythrocytes or in the GR and γ-GCS activity
(Table 1). However, there was 93% correlation between
GR activity of parasitized erythrocytes and parasitaemia
on the failure day.M
a
l
a
r
i
a
 
J
o
u
r
n
a
l
 
2
0
0
7
,
 
6
:
4
7
h
t
t
p
:
/
/
w
w
w
.
m
a
l
a
r
i
a
j
o
u
r
n
a
l
.
c
o
m
/
c
o
n
t
e
n
t
/
6
/
1
/
4
7
P
a
g
e
 
5
 
o
f
 
8
(
p
a
g
e
 
n
u
m
b
e
r
 
n
o
t
 
f
o
r
 
c
i
t
a
t
i
o
n
 
p
u
r
p
o
s
e
s
)
Table 1: 
Parasitized Erythrocytes Non-parasitized erythrocytes Free parasites*
ACR Starting day Failure ACR Starting day Failure ACR Starting day Failure
Starting day Failure day Starting day Failure day Starting day Failure day
GSH (nmol/mg protein) 5.612 ± 2.119a, h 11.725 ± 4.833b, h, j 5.847 ± 2.582c, j 16.324 ± 4.992a, i 21.636 ± 4.149b, i 19.093 ± 8.288c 2.416 ± 0.073 2.400 ± 0 2.400 ± 0
GR (mU/mg protein) 34.927 ± 14.777d 30.103 ± 10.171e 41.901 ± 17.110f 23.691 ± 8.145d 18.594 ± 5.442e 21.999 ± 8.903f 18.700 ± 5.867 19.711 ± 9.337 33.562 ± 14.436
γ-GCS (mU/mg protein) 20.692 ± 9.208 17.304 ± 8.478 28.141 ± 14.965g 17.444 ± 5.785 13.352 ± 6.793 13.150 ± 7.068g 10.043 ± 1.549 9.850 ± 1.501 10.5 ± 2.908
*In free parasites GR and γ-GCS enzymatic activity was not established because the protein quantity found was very low and in some cases not detectable, therefore the values shown correspond to 
enzymatic velocity (mU/ml).
Total glutathione concentration and glutathione reductase (GR) and γ-glutamylcysteine synthetase (γ-GCS) activities of parasitized erythrocytes non-infected erythrocytes and free parasite obtained from 
adequate clinical response patients (ACR) and failure therapeutic patients (FT). The values shown correspond to starting day (before ingestion AQ) and to failure day. We used the Mann-Whitney test in 
order to compare total glutathione and GR and γ-GCS activities in parasitized erythrocytes and non-parasitized erythrocytes on both days, and therapeutic responses groups. In addition, this test was used 
for to establish differences between total glutathione and enzymatic activity on starting day in parasitized erythrocytes between ACR patients and FT patients. Similarly for non-infected erythrocytes and free 
parasites. A matching test was applied (Wilcoxon test) to compare total glutathione and GR and γ-GCS activities in parasitized and non-infected erythrocytes and free parasites, between starting day and 
failure day in FT patients. P values statistically significant are shown.
a, b, cTotal glutathione in parasitized erythrocytes compared with total glutathione in non-infected erythrocytes for every therapeutic response group: ACR patients p (M-W) < 0.001; FT patients on starting p 
(M-W) = 0.003; and FT patients on failure day p (M-W) = 0.001.
d, e, fGR activity in parasitized erythrocytes compared with GR activity in non-infected erythrocytes for every therapeutic response group: ACR patients p (M-W) < 0.015; FT patients on starting p (M-W) = 
0.021; and FT patients on failure day p (M-W) = 0.013.
gγ-GCS activity in parasitized erythrocytes compared with γ-GCS activity in non-infected erythrocytes for every therapeutic response group: FT patients on failure day p (M-W) = 0.012.
hTotal glutathione in parasitized erythrocytes of ACR patients compared with FT patients on starting day p (M-W) = 0.001.
iTotal glutathione in non-parasitized erythrocytes of ACR patients compared with FT patients on starting day p (M-W) = 0.015
jTotal glutathione in parasitized erythrocytes of FT patients on starting day compared with FT patients on failure day p (Wilcoxon) = 0.017Malaria Journal 2007, 6:47 http://www.malariajournal.com/content/6/1/47
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Discussion
In this study, AQ failure in patients with malaria by P. fal-
ciparum was 31.25%, which is above the established value
to stop a treatment schaeme. This is the reason why it was
not possible to include a larger number of patients.
Luersen et al reported that non-parasitized erythrocytes
from ring-synchronous cultures of P. falciparum have 44%
more GSH than parasitized erythrocytes [22]. Although
samples in this study come from malaria patients, this is
in agreement with the results, where parasitized erythro-
cytes had lowered their total glutathione by more than
50%. In non-infected erythrocytes, there is no Plasmo-
dium-induced intra erythrocytic oxidative stress and glu-
tathione efflux and oxidation. However, it is important to
know if glutathione concentrations in this study corre-
spond to its reduced state, in order to confirm the hypoth-
esis formulated. The higher GR activity that was found on
the starting day in the Plasmodium-infected erythrocytes
could indicate that the contribution of the parasite to glu-
tathione metabolism depends on its reduction rather than
on its synthesis. GR activity found in free parasites sup-
ports this hypothesis. The 58% correlation between para-
sitaemia and GR activity in the free parasites in TF patients
on starting day should be noted. This might explain a dif-
ference in glutathione metabolism not influenced by the
presence of the drug and possibly favouring therapeutic
failure.
Glutathione could compete with AQ for the haem group,
possibly explaining therapeutic failure [7]. When glutath-
ione content and the activity of both enzymes (GR y γ-
GCS) in the different compartments studied are compared
with therapeutic response on the starting day (before
ingestion of AQ), we observed that parasitized and non-
parasitized erythrocytes of FT patients had higher amount
of total glutathione compared with ACR erythrocytes. This
is in agreement with reports by Safeukui et al., who found
that trophozoites of P. berghei CQ resistant strains isolated
from infected and untreated mice have higher glutathione
concentration in reduced form than in oxidized form,
compared with trophozoites of P. berghei CQ sensitive
and untreated [14]. The differences in parasitaemia do not
explain the results we obtained because, on the starting
day, parasitaemia is similar in both groups. A possible
explication could be that the resistant parasites have a bet-
ter redox system and, therefore, may have higher levels of
total glutathione, resulting from the novo synthesis and
reduction of oxidized glutathione. Differences in the
enzymatic activity could not be observed in this study
because, in the techniques used, NADH or NADPH could
be consumed by other enzymes.
The detection limit of total glutathione was 3.2 pmol,
which agrees with the report of Ivanov et al. that point out
a detection limit of 2–5 pmol [23]. Nevertheless, the small
amount of parasites possibly caused the total glutathione
to be below the detection limit in free parasites and, there-
fore, could have been the cause for not finding differences.
Also, on failure day it was examined if there was a differ-
ence between the parasitized and non-parasitized erythro-
cytes in the total glutathione and enzymatic activities; a
statistically higher total glutathione in non-infected eryth-
rocytes compared with parasitized erythrocytes was
found. These results agree with those found on the start-
ing day and therefore could also be explained by the con-
sumption of glutathione, product of the haemoglobin
metabolism in the red blood cell infected with Plasmo-
dium. In addition, was observed on failure day that GR as
well as γ-GCS activities are statistically higher in the
infected erythrocytes. It could be assumed that the main-
tenance of glutathione on the failure day depend on syn-
thesis as well as reduction. This difference between
starting and failure day possibly is due to the presence of
the drug that increases the number of free radicals and,
therefore, the parasite must also increase the glutathione
novo synthesis in order to compensate the difference in
reactive species that were controlled by greater GR activity
on the starting day when the drug was not present.
When establishing the comparison between the starting
day and failure day in TF patients at AQ, it was observed
that, on the failure day, the total glutathione in parasitized
erythrocytes was inferior to that of such patients in pre-
treatment starting day. As was mentioned above, it is pos-
sible that the presence of the drug increased the reactive
species and thus increased the consumption of glutath-
ione. This does not occur in the non-parasitized erythro-
cytes on the failure day, where the amount of total
glutathione continues to be the same as on starting day.
Nevertheless, these differences in the total glutathione of
both days could also be attributed to the difference in par-
asitaemias, since they were lower on the failure day com-
pared with starting day. Changes in enzymatic activities
between the starting day and failure day were not
observed. However, with the methodology used, was can-
not discard that some difference exists.
With the results obtained, was concluded that:
1) Independent of the therapeutic response and of the
treatment day (starting or failure), the total glutathione
was higher and GR activity was lower in the non-infected
erythrocytes compared with parasitized erythrocytes.
2) The higher GR activity in the infected erythrocytes on
the failure day could be due to a compensation mecha-
nism by lower total glutathione in this compartment.Malaria Journal 2007, 6:47 http://www.malariajournal.com/content/6/1/47
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3) The patients with TF had higher total glutathione in
parasitized and non-parasitized erythrocytes on the start-
ing day compared with the ACR patients, indicating a pos-
sible contribution to the therapeutic failure.
4) On failure day, the maintenance of glutathione in par-
asitized erythrocytes depends on synthesis and reduction,
possibly by the increase in the oxidative stress that AQ
generates.
5) In the FT patients, the total glutathione found in
infected erythrocytes was less on the failure day compared
with starting day. This is possibly due to the larger amount
of glutathione which is consumed in presence of the drug
and also to lower parasitaemia.
This study is the first attempt to explain P. falciparum ther-
apeutic failure through differences found in glutathione
metabolism in FT and ACR patients. Our results may
involve glutathione in the therapeutic response to antima-
larials; nevertheless, further studies are needed to prove
this relationship. It is also important to compare these
results with samples of healthy individuals to rule out
other possible differences. In addition, it is important to
perform more accurate enzymatic assays to discard differ-
ences in the enzymatic activities between the treatment
days and between the therapeutic response groups. It
would be useful to do a follow-up of the glutathione dur-
ing and after the malaric episode in patients with different
therapeutic response to establish if the glutathion (GSH
and GSSG) change during the infection and if they return
to the same level when the parasite is not present.
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